scholarly journals Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial Cancer

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Aneta Cymbaluk-Płoska ◽  
Anita Chudecka-Głaz ◽  
Ewa Pius-Sadowska ◽  
Agnieszka Sompolska-Rzechuła ◽  
Karolina Chudecka ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Endometrial Cancer ◽  
Serum Levels ◽  
Tumor Stage ◽  
Clinical Staging ◽  
Lipocalin 2 ◽  
Endometrial Cancer Risk ◽  
Diagnostic Potential ◽  
High Stage ◽  
The Relationship

The objectives of the study were to assess the relationship between the serum levels of MMP-9 and NGAL and the clinical staging and histopathological grade of the tumor. Lipocalin-2/NGAL and MMP-9 concentrations were quantified in serum by multiplex fluorescent bead-based immunoassays (Luminex Corporation, Austin, TX, USA). The AUC values for NGAL and MMP-9 were 0.9 and 0.78, respectively. The diagnostic potential of NGAL and MMP-9 in differentiating high-stage (FIGO III and IV) and low-stage (FIGO I and II) cancer and predicting the cell differentiation grade (G1 versus G3) on the basis of the analyses of AUC values was determined to be 0.91 and 0.79 for NGAL and 0.82 and 0.84 for MMP-9, respectively. Multifactorial logistic regression analysis in the final method revealed that NGAL and MMP-9 variables were independent of the endometrial cancer risk. OR values for NGAL and MMP-9 were 1.23 (95% CI 1.421–3.27; p=0.034) and 1.09 (95% CI: 1.38–4.12; p=0.026), respectively. The NGAL/MMP-9 complex may be useful in the assessment of tumor stage before surgical treatment.

scholarly journals The role of lipocalin-2 serum levels in the diagnostics of endometrial cancer

2019 ◽  
Vol 24 (3) ◽  
pp. 315-324 ◽  
Author(s):  
Aneta Cymbaluk-Płoska ◽  
Anita Chudecka-Głaz ◽  
Ewa Pius-Sadowska ◽  
Bogusław Machaliński ◽  
Agnieszka Sompolska-Rzechuła ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Serum Levels ◽  
Lipocalin 2

Evaluation of Chromogranin a Expression in Serum and Tissues of Breast Cancer Patients

2001 ◽  
Vol 16 (4) ◽  
pp. 268-272 ◽  
Author(s):  
L. Giovanella ◽  
M. Marelli ◽  
L. Ceriani ◽  
G. Giardina ◽  
S. Garancini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Chromogranin A ◽  
Neuroendocrine Differentiation ◽  
Serum Levels ◽  
Tumor Stage ◽  
Lymph Node Status ◽  
Ca 15.3 ◽  
Tumor Histology ◽  
The Relationship ◽  
Extent Of Disease

Human chromogranin A (CgA) is a member of the granin family and is widely distributed in large dense core granules of endocrine and neuroendocrine cells. A variety of non-neuroendocrine carcinomas arising in various tissues show patterns of neuroendocrine differentiation. Expression of CgA has been documented in epithelial cells of normal mammary gland as well as in breast cancers, and elevation of serum CgA has been detected in patients with breast cancer. Our study was undertaken to evaluate the relationship between serum CgA levels and neuroendocrine features in breast cancer. In addition, we evaluated the expression of serum CgA in patients affected by breast cancer compared to controls and the relationship between serum CgA and tumor histology, extent of disease, lymph node status, tumor stage and serum CA 15.3 levels. We enrolled 266 patients with infiltrating ductal or lobular breast carcinoma and a group of 100 age-matched healthy women serving as controls. Serum CgA and CA 15.3 were assayed by specific immunoradiometric methods. The overall sensitivity of CgA and CA 15.3 was 0.06 and 0.34, respectively (χ219.1, p<0.0005). No relationship was found between serum levels of CgA and tumor histology, extent of disease, lymph node status or tumor stage while serum levels of CA 15.3 were strongly correlated with all these variables but tumor histology. No relationship was found between serum levels of CgA and CA 15.3. Immunostaining against CgA, CgB, NSE and synaptophysin was performed on primary tumor tissue of 14 serum CgA-positive and 24 serum CgA-negative patients and was negative in all cases. We also evaluated eight cases of pathologically-proven neuroendocrine breast cancer: only four and two of these showed positive CgA immunostaining and increased serum CgA concentration, respectively. In conclusion, serum CgA assay offers no additional information regarding the presence, the extent and the histology of breast cancer compared to the CA 15.3 assay. Moreover, serum CgA was not an accurate marker to identify or exclude the rare neuroendocrine differentiation of breast cancer. We therefore conclude that CgA is not useful as a serum marker in breast cancer.

scholarly journals Oral Bisphosphonate Use and Risk of Postmenopausal Endometrial Cancer

2015 ◽  
Vol 33 (10) ◽  
pp. 1186-1190 ◽  
Author(s):  
Polly A. Newcomb ◽  
Michael N. Passarelli ◽  
Amanda I. Phipps ◽  
Garnet L. Anderson ◽  
Jean Wactawski-Wende ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cancer Risk ◽  
Postmenopausal Women ◽  
Treatment Of Osteoporosis ◽  
Endometrial Cancer Risk ◽  
Patients With Cancer ◽  
Oral Bisphosphonate ◽  
Intact Uterus ◽  
The Relationship

Purpose Bisphosphonates are common medications used for the treatment of osteoporosis and are also used to reduce metastases to bone in patients with cancer. Several studies, including the Women's Health Initiative (WHI), have found that use of bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies. This study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer. Methods We evaluated the relationship between use of oral bisphosphonates and endometrial cancer risk in a cohort of 89,918 postmenopausal women participating in the WHI. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. All women had an intact uterus at the time of study entry. Results During a median follow-up of 12.5 years, 1,123 women were diagnosed with incident invasive endometrial cancer. Ever use of bisphosphonates was associated with reduced endometrial cancer risk (adjusted hazard ratio, 0.80; 95% CI, 0.64 to 1.00; P = .05), with no interactions observed with age, body mass index, or indication for use. Conclusion In this large prospective cohort of postmenopausal women, bisphosphonate use was associated with a statistically significant reduction in endometrial cancer risk.

scholarly journals Association Between the -1031 (T/C) Polymorphism of TNF-α Gene and Biochemical Factors in Women With Polycystic Ovary Syndrome

2020 ◽  
Vol 24 (6) ◽  
pp. 486-497
Author(s):  
Mehdi Sahmani ◽  
◽  
Talaate Dabaghi Ghaleh ◽  
Maryam Yargholi ◽  
Farshad Foroghi ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Serum Levels ◽  
Inflammatory Factor ◽  
Ovary Syndrome ◽  
Healthy Women ◽  
Tnf Α ◽  
The Mean ◽  
The Relationship

Background: Tumor Necrosis Factor Alpha (TNF-α) gene, as an inflammatory factor, plays an important role in reproductive physiology, especially in women with Polycystic Ovary Syndrome (PCOS). Objective: This study aims to investigate the relationship between the -1031 T/C polymorphism of TNF-α gene and biochemical factors in women with PCOS. Methods: In this case-control study, participants were 106 women with PCOS and 114 healthy women referred to Kosar Hospital in Qazvin, Iran. The TNF-α gene’s polymorphism was determined using Polymerase Chain Reaction (PCR) technique and PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) method. Biochemical factors of serum levels were also measured in two groups. Logistic regression analysis examined the relationship between the frequency of alleles in different states and the risk of PCOS. Findings: There were statistically significant difference in the mean levels of total cholesterol, triglycerides, testosterone, two-hour blood glucose and body mass index between the groups, whose values were higher in women with PCOS compared to healthy women (P<0.001). In women with PCOS, the mean serum levels of triglyceride and high-density lipoprotein were significantly different between the three TT, CC, TC genotypes of TNF-α gene polymorphism (P<0.05). The results of regression analysis showed that the TT genotype had significant association with the risk of PCOS (OR=2.43, P=0.006, 95%CI: 1.28-2.62). Conclusion: It seems that there is a relationship between the -1301 (T/C) polymorphism of TNF-α gene and the risk of PCOS in women.

scholarly journals A genetic perspective on the relationship between non-cancerous gynecological diseases and endometrial cancer

2020 ◽  
Author(s):  
Pik Fang Kho ◽  
Sally Mortlock ◽  
Peter A.W. Rogers ◽  
Dale R. Nyholt ◽  
Grant W. Montgomery ◽  
...  
Keyword(s):  
Risk Factors ◽  
Endometrial Cancer ◽  
Cancer Risk ◽  
Genetic Correlation ◽  
Genetic Risk ◽  
Uterine Fibroids ◽  
Endometrial Cancer Risk ◽  
Gynecological Diseases ◽  
The Relationship ◽  
Shared Genetic

AbstractThe non-cancerous gynecological diseases, endometriosis, polycystic ovary syndrome (PCOS) and uterine fibroids, have been proposed as endometrial cancer risk factors; however, disentangling their relationships is complicated due to their shared risk factors and comorbidity. Using genome-wide association study (GWAS) summary data, we have explored the relationship between these non-cancerous gynecological diseases and endometrial cancer risk, assessing genetic correlations, causal relationships and shared genetic risk regions. Firstly, we found significant genetic correlation between endometrial cancer and PCOS (rG = 0.36, se = 0.12, P = 1.6×10−3), and uterine fibroids (rG = 0.24, se = 0.09, P = 5.4×10−3). Adjustment for genetically predicted body mass index (BMI; a risk factor for PCOS, uterine fibroids and endometrial cancer) substantially attenuated the genetic correlation between endometrial cancer and PCOS, but not uterine fibroids. Despite the observed genetic correlation, genetic causal inference tests (latent causal variable and Mendelian randomization analyses) did not support a causal relationship between any of the non-cancerous gynecological diseases and endometrial cancer. Gene-based association analysis revealed four shared endometriosis and endometrial cancer risk loci (9p21.3, 15q15.1, 17q21.32 and 3q21.3) and two shared uterine fibroid and endometrial cancer risk loci (5p15.33 and 11p13). In summary, we have shown that PCOS and uterine fibroids are genetically correlated with endometrial cancer, although the genetic architecture shared between endometrial cancer and PCOS likely relates to BMI. Furthermore, shared genetic risk regions, and thus potentially shared causal genes, were identified between the risk for endometrial cancer and endometriosis, and uterine fibroids.

Serum AMDL DR-70 levels: a new concept in the diagnosis and follow-up of colorectal carcinoma

2020 ◽  
Vol 14 (8) ◽  
pp. 621-628
Author(s):  
Serdar Saridemir ◽  
Hikmet E Güven ◽  
Bülent Aksel ◽  
Lütfi Doğan
Keyword(s):  
Colorectal Cancer ◽  
Serum Levels ◽  
Receiver Operating Curve ◽  
Control Group ◽  
Diagnostic Potential ◽  
Tumor Number ◽  
The Relationship ◽  
Experimental Group ◽  
Disease Grade

Aim: The purpose of this study was to determine the diagnostic potential of DR-70 assay in patients with colorectal cancer and to investigate the relationship between serum DR-70 levels and the biological characteristic of the tumor. Patients & methods: The experimental group included patients who were diagnosed with colorectal adenocarcinoma after biopsy specimen. The control group of this study consisted of patients whose total colonoscopy was reported as normal. Results: Serum levels of DR-70 was found to be significantly higher in patients with colorectal cancer than healthy participants (p = 0.001). Receiver operating curve analyses indicated a cut-off value of 1.69 μg/ml for serum DR-70 levels. Stage of the disease, grade of the tumor, number of metastatic lymph nodes and microsatellite instability status were significantly related to serum DR-70 levels (p = 0.001, p = 0.001, p = 0.001 and p = 0.002, respectively). Conclusion: It can be concluded that serum levels of DR-70 can be regarded as an indicator for the diagnosis of colorectal cancer.

scholarly journals Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; Results from the European prospective investigation into cancer and nutrition

2007 ◽  
Vol 120 (12) ◽  
pp. 2656-2664 ◽  
Author(s):  
Anne E. Cust ◽  
Naomi E. Allen ◽  
Sabina Rinaldi ◽  
Laure Dossus ◽  
Christine Friedenreich ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cancer Risk ◽  
Serum Levels ◽  
Endometrial Cancer Risk ◽  
C Peptide ◽  
Prospective Investigation

scholarly journals Serum concentrations of TFF3, S100-A11 and AIF-1 in association with systemic inflammatory response, disease stage and nodal involvement in endometrial cancer

Pteridines ◽  
2018 ◽  
Vol 29 (1) ◽  
pp. 6-12
Author(s):  
Radovan Pilka ◽  
David Neubert ◽  
David Stejskal ◽  
Gabriela Krejčí ◽  
Marek Švesták ◽  
...  
Keyword(s):  
Vitamin D ◽  
Endometrial Cancer ◽  
Lymph Node ◽  
Endometrial Hyperplasia ◽  
Serum Levels ◽  
Tumor Stage ◽  
Disease Stage ◽  
Creatinine Ratio ◽  
Serum Concentrations ◽  
Urinary Neopterin

AbstractTo compare preoperative intestinal trefoil factor 3 (TFF3), allograft inflammatory factor-1 (AIF-1) and calgizzarin (S100-A11) serum levels in patients with endometrial cancer, endometrial hyperplasia and in healthy female controls. Serum levels of TFF3, S100- A11 and AIP-1 were analyzed in 98 consecutive patients with histologically verified endometrial cancer, in 43 patients with endometrial hyperplasia diagnosed during hysteroscopy and 24 controls with benign disease. Results were correlated with urinary neopterin/creatinine ratio, serum kynurenine, tryptophan, retinol, alpha-tocopherol, vitamin D, citrulline, C-reactive protein, interleukin-6 and clinical characteristics. S100-A11, and AIF-1 levels were higher in endometrial hyperplasia patients than in controls, and also significantly higher in endometrial cancer than in patients with endometrial hyperplasia. Serum concentrations of TFF3 and S100-A11 were associated with tumor stage and lymph node status. TFF3 exhibited positive correlation with age, IL-6, vitamin D, kynurenine, urinary neopterin/creatinine ratio and kynurenine/tryptophan ratio. S100-A11, as well as AIF-1 correlated positively with Il-6 and TFF3. TFF3, S100-A11 and AIF-1 represent potential biomarkers in patients with endometrial cancer. TFF3 and S100-A11 increase with tumor stage and lymph node involvement, reflecting higher tumor mass that is also associated with increased concentration of biomarkers of immune dysfunction.

scholarly journals Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis

2021 ◽  
Author(s):  
Emma Hazelwood ◽  
Eleanor Sanderson ◽  
Vanessa Y Tan ◽  
Katherine S Ruth ◽  
Timothy M Frayling ◽  
...  
Keyword(s):  
Risk Factors ◽  
Endometrial Cancer ◽  
Cancer Risk ◽  
Mendelian Randomization ◽  
Endometrial Cancer Risk ◽  
Mediating Role ◽  
Bioavailable Testosterone ◽  
The Relationship ◽  
Randomization Analysis

Background: Endometrial cancer is the most common gynaecological cancer in high-income countries. Elevated body mass index (BMI) is an established modifiable risk factor for this condition and is estimated to confer a larger effect on endometrial cancer risk than any other cancer site. However, the molecular mechanisms underpinning this association remain unclear. We used Mendelian randomization (MR) to evaluate the causal role of 14 molecular risk factors (hormonal, metabolic, and inflammatory markers) in endometrial cancer risk. We then evaluated and quantified the potential mediating role of these molecular traits in the relationship between BMI and endometrial cancer. Methods and Findings: Genetic instruments to proxy 14 molecular risk factors and BMI were constructed by identifying single-nucleotide polymorphisms (SNPs) reliably associated (P < 5.0 x 10-8) with each respective risk factor in previous genome-wide association studies (GWAS). Summary statistics for the association of these SNPs with overall and subtype-specific endometrial cancer risk (12,906 cases and 108,979 controls) were obtained from a GWAS meta-analysis of the Endometrial Cancer Association Consortium (ECAC), Epidemiology of Endometrial Cancer Consortium (E2C2), and UK Biobank. SNPs were combined into multi-allelic models and odds ratios (ORs) and 95% confidence intervals (95% CIs) were generated using inverse-variance weighted random-effects models. The mediating roles of the molecular risk factors in the relationship between BMI and endometrial cancer were then estimated using multivariable MR. In MR analyses, there was strong evidence that BMI (OR per SD increase: 1.88, 95% CI: 1.69 to 2.09, P = 3.87 x 10-31), total testosterone (OR per inverse normal transformed nmol/L increase: 1.64, 95% CI: 1.43 to 1.88, P = 1.71 x 10-12), bioavailable testosterone (OR per inverse normal transformed nmol/L increase: 1.46, 95% CI: 1.29 to 1.65, P = 3.48 x 10-9), fasting insulin (OR per natural log transformed pmol/L increase: 3.93, 95% CI: 2.29 to 6.74, P = 7.18 x 10-7) and sex hormone-binding globulin (SHBG, OR per inverse normal transformed nmol/L increase: 0.71, 95% CI: 0.59 to 0.85, P = 2.07 x 10-4) had a causal effect on endometrial cancer risk. Additionally, there was suggestive evidence that total serum cholesterol (OR per mg/dL increase: 0.90, 95% CI: 0.81 to 1.00, P = 4.01 x 10-2) had an effect on endometrial cancer risk. In mediation analysis using multivariable MR, we found evidence for a mediating role of fasting insulin (19% total effect mediated, 95% CI: 5 to 34%, P = 9.17 x 10-3), bioavailable testosterone (15% mediated, 95% CI: 10 to 20%, P = 1.43 x 10-8), and SHBG (7% mediated, 95% CI: 1 to 12%, P = 1.81 x 10-2) in the relationship between BMI and endometrial cancer risk. The primary limitations of this analysis include the assumption of linear relationships across univariable and multivariable analyses and the restriction of analyses to individuals of European ancestry. Conclusions: Our comprehensive Mendelian randomization analysis provides insight into potential causal mechanisms linking BMI with endometrial cancer risk and suggests pharmacological targeting of insulinemic and hormonal traits as a potential strategy for the prevention of endometrial cancer.

Sign in / Sign up

Export Citation Format

Share Document